Jasper Completes Kira Acquisition, Eyes Multiple Clinical Milestones Through 2027; Stock Down

Source and reference

source on Google Add Now Jasper Therapeutics, Inc. ( JSPR ), a clinical-stage biotechnology company, announced that it has completed the acquisition of Kira Pharmaceuticals in an all-stock transaction. In addition, the company provided an update on the near-term milestones as a combined company. In connection with the acquisition of Kira, each holder of Jasper common stock immediately before closing will be entitled to a non-transferable contingent value right or CVR. CVR holders will be eligible to receive up to $30 million in payments if certain conditions related to the receipt and monetisation of a priority review voucher (PRV) are met. The combined company will focus on advancing the pipeline of therapies for immunologically driven disorders, including KP-104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and nephrology disorders; Briquilimab for transplant and...